HC Wainwright Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD)

HC Wainwright assumed coverage on shares of Aardvark Therapeutics (NASDAQ:AARD - Free Report) in a research note published on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $40.00 price target on the stock.

A number of other research analysts have also commented on AARD. Royal Bank Of Canada dropped their price objective on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Bank of America boosted their price target on Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Morgan Stanley assumed coverage on Aardvark Therapeutics in a research report on Monday, March 10th. They set an "overweight" rating and a $29.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 target price on shares of Aardvark Therapeutics in a report on Tuesday, April 1st. Finally, Wall Street Zen cut shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Aardvark Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.

Aardvark Therapeutics Stock Performance

Shares of Aardvark Therapeutics stock traded up $0.04 on Monday, hitting $13.56. The stock had a trading volume of 67,627 shares, compared to its average volume of 79,066. Aardvark Therapeutics has a 52-week low of $4.88 and a 52-week high of $19.58. The business has a 50 day moving average price of $11.17.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.01).

Institutional Trading of Aardvark Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC acquired a new stake in shares of Aardvark Therapeutics during the 1st quarter valued at approximately $88,000. Goldman Sachs Group Inc. acquired a new position in Aardvark Therapeutics during the first quarter worth $153,000. Adage Capital Partners GP L.L.C. purchased a new stake in Aardvark Therapeutics during the first quarter worth $1,878,000. Braidwell LP acquired a new stake in Aardvark Therapeutics in the first quarter valued at $3,755,000. Finally, Cormorant Asset Management LP acquired a new stake in Aardvark Therapeutics in the first quarter valued at $6,009,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.